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Kidney transplantation is the best treatment for end-stage renal disease, but its implementation is limited by organ
shortage and immune rejection. Side effects of current immunosuppressive drugs, such as nephrotoxicity,
opportunistic infection, and tumorigenic potential, influence long-term graft outcomes. In recent years, continued
research and subsequent discoveries concerning the properties and potential utilization of mesenchymal stem
cells (MSCs) have aroused considerable interest and expectations. Biological characteristics of MSCs, including
multi-lineage differentiation, homing potential, paracrine effect and immunomodulation, have opened new
horizons for applications in kidney transplantation. However, many studies have shown that the biological activity
of MSCs depends on internal inflammatory conditions, and the safety and efficacy of the clinical application of
MSCs remain controversial. This review summarizes the findings of a large number of studies and aims to provide
an objective viewpoint based on a comprehensive analysis of the presently established benefits and obstacles of
implementing MSC-based therapy in kidney transplantation, and to promote its clinical translation.Background
The number of patients with chronic kidney disease and
end-stage renal disease (ESRD) increases each year. Kid-
ney transplantation is an effective long-term means of
treatment for ESRD, but is closely accompanied by a high
risk of post-transplant rejection. With improvements in
tissue type matching and the use of new immunosuppres-
sive agents, the danger of acute renal post-transplant
rejection has been greatly reduced, but the hazards for
long-term graft survival have remained unchanged.
Regular immunosuppressive drug protocols mainly in-
clude corticosteroids in combination with calcineurin
inhibitors, purine/pyrimidine synthesis inhibitors, and
sometimes lymphodepletion [1]. However, their use
should be gradually tapered off to lower the risk of oppor-
tunistic infections and malignancies, as well as to prevent
long-term toxicity to the central nervous, gastrointestinal
and hematopoietic systems and kidneys. Therefore, there
is a substantial need for novel immunosuppressive therap-
ies that have few side effects, while maintaining efficacy.
Mesenchymal stem cells (MSCs) are mesoderm-
derived multipotent stromal cells that have high self-* Correspondence: houjianquan@suda.edu.cn
Department of Urology, The First Affiliated Hospital of Soochow University,
188 Shizi Road, Suzhou 215006, Jiangsu, PR China
© 2016 Chen and Hou. Open Access This art
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zerenewal and multi-lineage differentiation potential, an
immunomodulatory and inflammatory homing capacity,
and the ability to repair damaged tissues and organs.
They are widespread in many tissues of the body and
can be cultured and multiplied in vitro, with the ability
to differentiate into bone, cartilage, fat, muscle, nerves
and other tissues under certain conditions [2, 3].
The underlying immunomodulatory mechanism of ac-
tion of MSCs has been widely recognized, and its effect-
iveness has also been confirmed by early clinical trials in
the treatment of graft-versus-host disease (GVHD) [4].
Thus, we can speculate that the application of MSCs in
kidney transplantation will not only reduce the amount
of immunosuppressive drugs required, but also enhance
the renal function of patients and improve their long-
term survival.
Biological characteristics of MSCs
MSCs are pluripotent, long, shuttle-shaped, fibroblast-
like stem cells that are present in almost all tissues and
organs, including the bone marrow, periosteum, fat tis-
sue, pulp, synovium, umbilical cord, placenta, amniotic
fluid and fetal tissues.
To date, no studies have reported the discovery of spe-
cific MSC surface markers. In view of this, in 2006, the
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must adhere to plastic under standard tissue culture
conditions; (2) MSCs must express specific cell surface
markers such as CD73, CD90 and CD105, while lacking
the expression of hematopoietic stem cell markers and
autologous transplant rejection antigens such as CD45,
CD34, CD14, CD11b, CD79α, CD19 and human leukocyte
antigen (HLA)-DR; (3) in vitro, these cells must have the
capacity to be induced to differentiate into adipocytes, os-
teoblasts and chondrocytes.
MSCs have multi-lineage differentiation potential;
in vitro, they can differentiate into mesoderm lineage
(bone, cartilage, fat, and connective tissues) and transdif-
ferentiate into both ectodermal (nerve and epithelial tis-
sues) and endodermal cells (muscle and liver cells) [2,
3]. Thus, MSCs have become the preferred seed cells for
tissue engineering.
After systemic infusion, MSCs can preferentially mi-
grate into sites of inflammation and injury and tumors.
This ‘homing capacity’ of MSCs can be used in drug or
gene carrier applications for targeted treatment of dis-
eases or killing of tumor cells [6]. In the situation of
renal ischemia-reperfusion injury, MSCs move towards
renal tissues and repair ischemic renal tubular injury.
Through paracrine and endocrine secretion of various
cytokines, MSCs inhibit apoptosis and fibrosis of dam-
aged renal tissues, regulate immune and inflammatory
responses, and promote angiogenesis to stimulate renal
tissue regeneration instead of directly differentiating into
renal tubular epithelial cells [7].
Plasticity of the immunoregulatory and
anti-inflammatory properties of MSCs
MSCs constitutively express low levels of major histo-
compatibility complex (MHC) class I molecules, but do
not express MHC class II and costimulatory molecules,
including B7-1 (CD80), B7-2 (CD86) and CD40 [8],
resulting in the absence of a HLA allogeneic barrier dur-
ing their transplantation. Thus, the lack of immunogen-
icity of MSCs provides a theoretical basis for their use in
extensive transplantation, such that a cord blood bank,
for example, could be established.
MSC-mediated immunosuppression is elicited by
interferon (IFN)-γ in the presence of other proinflamma-
tory cytokines, tumor necrosis factor-α, interleukin (IL)-
1α, or IL-1β [9, 10]. This activation step has also been
shown in vivo in a GVHD model, since recipients of IFN
−/− T cells did not respond to MSC treatment and suc-
cumbed to GVHD [11]. The immunosuppression of
MSCs was absent in IFN-γ receptor 1−/− mice, highlight-
ing the importance of IFN-γ in this process [10].
MSCs exert immunosuppressive effects by secreting
bioactive molecules and through cell-to-cell contact
(Fig. 1). They can inhibit the activation of macrophagesto release proinflammatory cytokines and promote anti-
inflammatory cytokine secretion. By secreting the sol-
uble antigen IL-6 and prostaglandin E2, MSCs suppress
differentiation of monocytes into, and interfere with the
development, differentiation and maturation of, den-
dritic cells. Furthermore, MSCs can reduce the secretion
of IFN-γ in natural killer cells and change their pheno-
type, inhibiting their proliferation, cytokine secretion
and cell killing role by the activation of Toll-like recep-
tor (TLR)4 [12]. Together with IFN-γ stimulation, indo-
leamine 2,3-dioxygenase (IDO) secreted by MSCs can
suppress T-cell proliferation by degrading tryptophan, an
essential amino acid for the induction of the T-cell cycle,
leading to arrest in G0/G1 phase. MSCs increase CD4+
CD25+ FoxP3+ T regulatory cell function and can cause
the arrest of B lymphocytes in the G0/G1 phase [13]. Me-
diated by T cells, MSCs inhibit the maturation, migration,
proliferation and antibody production of B cells [14].
MSC immunosuppressive functions are ‘licensed’ by the
inflammation environment [10], and this inflammatory
status determines the immunoregulatory effect of MSCs.
Strong inflammation causes MSCs to suppress the im-
mune response, whereas weak inflammation leads to im-
mune reaction enhancement by MSCs. MSC1 and MSC2
represent the proinflammatory and anti-inflammatory
phenotypes of MSCs, respectively [15]. The activation of
TLRs can affect the inflammatory functions of MSCs [16].
In the absence of proinflammatory cytokines, the activa-
tion of TLR4 can result in the differentiation of MSCs into
the MSC1 phenotype. Conversely, differentiation into the
MSC2 phenotype can be induced by the delivery of anti-
inflammatory signals to MSCs through TLR3 [15, 17].
MSCs in kidney transplantation
Since MSCs can exert both anti-ischemia-reperfusion in-
jury and anti-post-transplant rejection functions, these
cells are of particular interest in kidney transplantation.
Preclinically, MSC therapy positively influences renal
function and graft survival [18, 19]. Since the first suc-
cessful clinical application of MSCs in 2004 [4], research
into MSC therapeutic applications has expanded to the
point where there are now more than 500 registered
clinical trials (http://clinicaltrials.gov/). However, only
nine MSC clinical trials in kidney transplantation have
been registered (Table 1). Despite this limited number,
translation of MSCs from the bench to bedside for use
in kidney transplantation is highly possible.
Reinders et al. [20] have demonstrated that combined
treatment with autologous bone marrow-derived MSCs
(BM-MSCs) and a maintenance immunosuppressant al-
leviates acute rejection and interstitial fibrosis/tubular
atrophy up to 24 weeks after MSC infusion. Other find-
ings have shown that autologous MSCs injected together
with a maintenance immunosuppressant resulted in
Fig. 1 Immunomodulatory effects of mesenchymal stem cells (MSCs) on immune cells. MSCs inhibit the activation of macrophages and proliferation
of T cells, regulate the activation and differentiation of B cells, and suppress natural killer (NK) cell proliferation. They inhibit monocyte differentiation
into dendritic cells (DC) and enhance the cell function of CD+Cd25+FoxP3+ T regulatory (Treg) cells. They secrete inhibitory factors or make cell-to-cell
contacts with various types of immune cells to exert their immunosuppressive effects and treat a variety of immune system disorders. IDO indoleamine
2,3-dioxygenase, IFN interferon, IL interleukin, PGE2 prostaglandin E2, TLR Toll-like receptor
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[21]. Peng et al. [22] described a significant reduction of
tacrolimus dose accompanied by stable renal function
after allogeneic MSC application. Crop et al. [23] sug-
gested that MSCs can inhibit the proliferation of T cells
and reduce graft inflammation, indicating that MSCTable 1 Registered clinical trials of mesenchymal stem cells in kidne
NCT Status Title
NCT02409940 Recruiting To elucidate the effect of mesenchymal stem c
on the T-cell repertoire of kidney transplant pa
NCT02387151 Recruiting Allogeneic mesenchymal stromal cell therapy
renal transplant recipients
NCT02057965 Recruiting Mesenchymal stromal cell therapy in renal reci
NCT02012153 Recruiting Mesenchymal stromal cells in kidney transplan
recipients
NCT00659620 Unknown Mesenchymal stem cell transplantation in the
treatment of chronic allograft nephropathy
NCT00734396 Completed Mesenchymal stem cells and subclinical rejecti
NCT00752479 Terminated Mesenchymal stem cells under basiliximab/low
dose RATG to induce renal transplant toleranc
NCT00658073 Completed Induction therapy with autologous mesenchym
stem cells for kidney allografts
NCT01429038 Recruiting Mesenchymal stem cells after renal or liver
transplantation
BM-MSC bone marrow-derived mesenchymal stem cell, MSC mesenchymal stem celadministration can be a promising cell therapy in clinical
organ transplantation. Vanikar et al. [24] provided evi-
dence that adipose-derived mesenchymal stem cells
(ADMSCs) combined with hematopoietic stem cell
transplantation perform more effectively than trans-
plantation alone. Results from studies by Trivedi et al.y transplantation (ClinicalTrial.gov, updated July 2015)






in Leiden, Netherlands Allogeneic; BM-MSC March 2015
pients Leiden, Netherlands Autologous; BM-MSC March 2014
t Bergamo, Italy Autologous; BM-MSC December 2013
Fuzhou, Fujian Autologous; BM-MSC May 2008
on Leiden, Netherlands Autologous; BM-MSC February 2009
e
Bergamo, Italy Autologous; BM-MSC May 2008
al Fuzhou, Fujian Autologous; BM-MSC March 2008
Liege, Belgium Allogeneic; BM-MSC February 2012
l, NCT ClinicalTrials.gov identifier, RATG rabbit antithymocyte globulin
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transplant ADMSCs combined with hematopoietic stem
cells minimized the overall application of immunosup-
pressants in kidney transplantation. Tan et al. [27] con-
firmed that inoculation with MSCs significantly reduced
acute rejection incidence and opportunistic infections,
while maintaining renal function better than that of con-
trols. Donor MSC injection into the iliac bone at the
time of kidney transplantation was reported to be safe
[28]. A large-sample meta-analysis has also confirmed
the clinical safety of MSC therapies [29].
Problems in the clinical translation of MSCs
Although MSCs exhibit great potential in most preclin-
ical and clinical data, many questions remain to be re-
solved. Furthermore, the optimal source of MSCs, the
optimal time window, dosage, route and frequency of
MSC administration, post-transplantation safety and
long-term prognosis have still not been determined.
MSC sources
MSCs are found in almost all postnatal organs and tissues,
including fat, bone, cartilage, umbilical cord, cord blood,
synovium, synovial fluid, muscle, skin and pulp. MSCs
from different sources possess similar morphologies and
express identical surface markers, but they do show differ-
ences in some biological characteristics. BM-MSCs are an
important part of the bone marrow microenvironment,
which promotes the function of hematopoietic stem cells
through the secretion of IL-1a, IL-1b, IL-6, IL-7, IL-8, IL-
11, IL-14, IL-15, leukemia inhibitory factor, stem cell
factor, thrombopoietin, fetal liver tyrosine kinase (Flt)-3
ligand, macrophage colony-stimulating factor, granulocyte
colony-stimulating factor, and granulocyte-macrophage
colony-stimulating factor [30]. Umbilical cord blood mes-
enchymal stem cells are the youngest MSCs, with the
highest potential and lowest immunogenicity [31, 32]. Hu-
man umbilical cord MSCs are mainly isolated from Whar-
ton’s jelly in the umbilical cord, which can be easily,
noninvasively and painlessly obtained without causing ad-
verse effects on the fetus and mother, can be utilized with-
out ethical restrictions, and does not produce teratomas
[33]. ADMSCs have many sources, and these cells are easy
to isolate and can be repeatedly collected with less pain to
the donor. Human amniotic MSCs can be derived from
abandoned amniotic membranes and possess low im-
munogenicity and multi-lineage differentiation, as well as
anti-inflammatory abilities similar to those of BM-MSCs.
The most promising candidate source of MSCs for cell
therapy continues to be debated.
Autologous or allogeneic MSCs
Thus far, most studies have used autologous cells. Togel
et al. [34] reported that autologous MSCs were morepotent than allogenic MSCs in a rat acute renal failure
model. However, it takes several weeks to months to
manufacture autologous cells due to the expansion
period, quality controls and logistics, and this period of
time is too long for patients in need of treatment. More-
over, MSCs derived from patients with renal disease
have a lower capacity for kidney regeneration [35].
Allogeneic MSCs offer an ‘off the shelf ’ advantage for
clinical use and have the potential to be mass-produced
rapidly [36]. This would significantly decrease costs and
the number of procedures, and enable use of cells from
young healthy donors that may exhibit higher efficacy
than cells from older individuals.
Timing of administration of MSCs
In a mouse model of GVHD, MSCs were most effective
when administered at 3, 8, or 20 days after bone marrow
transplantation, and these cells had no protective effect
when applied on the day of transplantation, suggesting
that a certain proinflammatory environment is necessary
for MSCs to polarize into an anti-inflammatory pheno-
type [11, 17]. In contrast, Casiraghi et al. [37] assumed
that better immune suppression by MSCs can be
achieved when they are injected before transplantation
rather than after it. Perico et al. [21, 38] also reported a
decrease in kidney function when MSCs were adminis-
tered within a week after transplantation. Therefore, the
optimal timing for MSC administration remains under
discussion.
Route of administration of MSCs
To date, most trials in kidney transplantation have used
intravenous infusion of MSCs. However, most of the
cells accumulated in the lungs after administration and
only a small number of cells reached the transplanted
kidney, implying that most MSCs do not play a substan-
tial role in the target tissue. Lung entrapment may be
due to the small capillary size, large capillary network,
and strong adhesion properties of MSCs. Increasing the
number of administered MSCs to compensate for this
disadvantage may cause unwanted side effects such as
embolism [39]. Zonta et al. [40] reported that local arterial
administration is more effective than systemic intravenous
administration, while not causing arterial thrombosis, in-
fections, or other adverse reactions.
Dose of MSCs
The application of MSCs in a dose of 0.4–10 × 106 cells
per kilogram of body weight in humans is reportedly the
most appropriate, since this dose does not result in sig-
nificant adverse effects. However, a high-dose (450 × 106
cells) infusion of MSCs in adult sheep was well tolerated
and proven safe [41].
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No long-lasting response was observed in children with
steroid-resistant GVHD who received one infusion of
MSCs, whereas two or more infusions led to better re-
sults [42]. However, Franquesa et al. [43] reported that a
single delayed MSC injection was effective for the long-
term protection of kidney allografts. Therefore, the most
effective number and frequency of MSC infusions are
uncertain and still to be determined.
Diversity in the mechanisms of action of MSCs derived
from different species
Murine MSCs exert immunosuppressive effects through
nitric oxide generated by inducible nitric oxide synthase,
whereas human MSCs use IDO as a major effector mol-
ecule. To eliminate species disparities that cause varia-
tions in different studies, an IDO-expressing humanized
MSC mouse model has been created to mimic the hu-
man system [44].
Synergistic role of MSCs with immunosuppressive drugs
Interestingly, MSCs perform better under the conditions
of an immunosuppressant-resistant acute inflammatory
disease. Le Blanc et al. [4] reported the treatment of se-
vere steroid- and cyclosporine-resistant GVHD with
MSCs. Sun et al. [45] described the profound therapeutic
effect of human umbilical cord MSCs in severe and re-
fractory systemic lupus erythematosus. Dalal et al. [46]
found that patients with severe, non-drug-responsive
Crohn’s disease can be treated with MSCs. However, the
treatment of GVHD with a combination therapy of Pro-
chymal (an MSC-based product) and steroids had no
therapeutic effect [47]. The combined administration of
MSCs with low-dose cyclosporine A (CsA) reversed the
protective influence of CsA and accelerated allograft re-
jection [48]. Zhang et al. [49] found that, when com-
bined with low-dose CsA, MSCs could not prolong
animal survival compared with CsA monotherapy.
Therefore, the application of MSCs is most feasible in
the therapy of immunosuppressant-resistant patients.
Other potential risks of MSCs
Other adverse events reported after MSC transplantation
include fever, fungal infection, organ system complica-
tions (neurological, pulmonary, cardiovascular, gastro-
intestinal and renal, and hematologic), high recurrence
rate, tumor growth and metastasis, and even death [29].
MSCs comprise a rare population of 0.001–0.01 % of
all nucleated cells in the bone marrow, so a sufficient
number of MSCs cannot be produced in 30 % of patients
with recurrent bone marrow biopsy [50]. Moreover, large
numbers of MSCs have to be expanded in vitro to obtain
amounts needed for clinical treatment and this may
change their biological characteristics and result in celltransformation. There is also a risk of microbial contam-
ination during in vitro artificial cell expansion of MSCs.
Thus, MSC engraftment requires rigorous bacterial test-
ing, as well as control of the time and dose. Moreover,
whether MSCs are traditional ‘stem cells’ remains con-
troversial. For example, both MSCs and fibroblasts have
a similar appearance, surface markers, and differenti-
ation ability. Furthermore, lacking in homogeneity and
comparability, current clinical trials on MSC transplant-
ation do not ensure stable and reproducible clinical effi-
cacy. The long-term safety of MSC therapy is also not
supported by data from large-scale, clinical, double-
blind, randomized and controlled trials.
Conclusion
Since its first long-term success in 1954, kidney trans-
plantation has represented the best treatment for pa-
tients with ESRD. Immunosuppressive drugs taken by
patients after transplantation heighten the risk of oppor-
tunistic infections and organ toxicity, which can affect
the quality of life of patients as well as graft survival.
MSCs have recently emerged as a prominent candidate
for cell-based therapies for GVHD [4] and kidney trans-
plantation [22, 27], and in many other clinical areas.
Four main characteristics predetermine the clinical ap-
plications of MSCs: (1) homing to damaged tissues and
inflammatory sites; (2) differentiation into various cell
types and tissues; (3) secretion of bioactive molecules;
(4) immunomodulation by their immunosuppressive and
anti-inflammation properties. The efficacy of MSC ther-
apy depends on the relative amounts of proinflammatory
and anti-inflammatory cytokines, and pretreatments
with proinflammatory cytokines (such as IFN-γ) improve
the efficacy of MSC-based therapy [11]. Therefore, to
optimize therapy, feasible approaches and relevant bio-
markers are needed so that the inflammatory status of
patients at the time of MSC infusion can be monitored.
Numerous preclinical trials have shown that MSCs ef-
fectively improve outcome after kidney transplantation,
but their value is limited due to the different mecha-
nisms of action of human and murine MSCs. Although
many clinical trials have demonstrated promising out-
comes of MSC-based therapy, the best source of MSCs,
the optimal timing, dosage, route and frequency of MSC
administration, as well as long-term post-transplantation
safety remain unclear. Nevertheless, we expect that
MSCs will contribute substantially to the success of hu-
man kidney transplantation, while large-scale, multi-
center clinical trials are needed to further validate their
clinical effects.
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